[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiyuan Hospital of China Academy of Chinese Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":148},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,71,95,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632802","clinical-efficacy-evaluation-of-chaizhi-hewei-decoction-in-the-treatment-of-non-erosive-reflux-disease-with-liver-stomach-disharmony-syndrome-100632802",false,"NCT07518420","Clinical Efficacy Evaluation of Chaizhi Hewei Decoction in the Treatment of Non-Erosive Reflux Disease With Liver-Stomach Disharmony Syndrome","Inclusion Criteria:\n\n1. Meet thediagnosis criteria for NERD;\n2. GERD Q scale score \\>8 points;\n3. Meet the criteria for the liver-stomach disharmony syndrome in traditional Chinese medicine;\n4. Age between 18-70 years old;\n5. Participants are informed and voluntarily sign the informed consent form. -\n\nExclusion Criteria:\n\n1. Patients with active gastric or duodenal ulcers, gastritis with active bleeding, severe dysplasia of the gastric mucosa, or suspected malignancy; patients with achalasia or post-achalasia surgery; and patients with functional heartburn.\n2. Patients with severe primary diseases of the cardiovascular, hepatic, renal, hematological, or respiratory systems, or malignant tumors.\n3. Patients with mental disorders (e.g., schizophrenia, bipolar affective disorder, depression, anxiety, obsessive-compulsive disorder) and those with intellectual or language impairments.\n4. Pregnant or breastfeeding women.\n5. Patients allergic to any components of this preparation.\n6. Patients currently taking medications that may affect the outcome of this study (e.g., proton pump inhibitors, potassium-competitive acid blockers, Tongjiang granules, etc.).\n7. Patients currently participating in or having participated in other drug clinical trials within the past 4 weeks.\n8. Patients with suspected or confirmed history of alcohol or substance abuse, anxiety, or depression; or, according to the investigator's judgment, other conditions that may reduce the likelihood of enrollment or complicate the enrollment process, such as frequent changes in work environment that may lead to loss of follow-up.\n\n   \\-","ALL","18 Years","70 Years",{"count":19,"type":20},66,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study focuses on patients with NERD (gastroesophageal reflux disease) and liver-gallbladder disharmony syndrome as its research subjects. It conducts a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the Chai Zhi He Wei formula in terms of symptom improvement, quality of life, and adverse reactions. On one hand, this research aims to enhance the level of evidence-based medicine for TCM syndrome differentiation and treatment of NERD. On the other hand, it seeks to reduce the dosage of PPIs (proton pump inhibitors) or discontinue their use, addressing the side effects caused by PPI overuse, and serving as a leading example for TCM clinical research. Lastly, the study aims to optimize the efficacy of Tongjiang granules and address potential safety concerns, such as diarrhea.",[26],"Non-erosive Reflux Disease (NERD)",[28,29,30],"Chaizhi Hewei Decoction","Liver-Stomach Disharmony Syndrome","randomized controlled trial","NOT_YET_RECRUITING","2026-04-06",{"date":34,"type":35},"2026-04-08","ACTUAL",{"date":37,"type":20},"2026-05-15",{"date":39,"type":20},"2028-08-31",{"name":41,"class":42},"Xiyuan Hospital of China Academy of Chinese Medical Sciences","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100581049","phase-3-clinical-study-on-the-intervention-of-xuesaitong-soft-capsules-in-post-intervention-patients-with-acute-coronary-syndrome-and-clinical-research-protocol-100581049","NCT06845254","Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol","Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome After Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Patients diagnosed with acute ST-segment elevation myocardial infarction, acute non-ST-segment elevation myocardial infarction, or unstable angina according to Western medical standards. Inclusion Criteria.\n2. Within 4 weeks post-PCI.\n3. Aged between 18 and 80 years, both male and female.\n4. Voluntarily participating in the clinical trial, having signed the informed consent form.\n\nExclusion Criteria:\n\n1. Uncontrolled hypertension after medication (systolic BP \\>180mmHg or diastolic BP \\> 110mmHg).\n2. Increased bleeding risk: history of hemorrhagic stroke; intracranial aneurysm; major trauma or surgery within the past month (including Exclusion Criteria bypass surgery); active bleeding disorders.\n3. History of gastrointestinal ulcers or significant gastrointestinal bleeding.\n4. Severe organic heart disease, such as LVEF \\\u003C 35% or NYHA\u002FKillip heart function grade IV.\n5. History of malignant arrhythmias within the past year (arrhythmias affecting hemodynamics requiring medication or electrical cardioversion, or requiring CPR), congenital heart disease, or malignant tumors.\n6. Severe liver or kidney dysfunction: ALT or AST ≥ 3×ULN, TBIL≥ 2×ULN, or creatinine clearance \\\u003C 30ml\u002Fmin.\n7. Pregnant or lactating women.\n8. Recent blood donation or significant blood loss within the past 3 months (≥400ml).\n9. History of alcohol abuse (≥28 standard units\u002Fweek for males, ≥21 standard units\u002Fweek for females) or frequent alcohol consumption in the past 6 months (≥14 standard units\u002Fweek).\n10. History of drug abuse or dependence within the past year. Participation in other clinical trials and taking trial drugs within the past 3 months.\n11. Allergy or intolerance to aspirin or P2Y12 receptor inhibitors.\n12. Allergy to any components of the trial drug.\n13. Other conditions deemed inappropriate for participation by the nvestigator","80 Years",{"count":53,"type":20},400,[55],"PHASE3","To assess the effects of Xuesaitong soft capsules on platelet function, clinical efficacy, prognosis, and safety in the treatment of acute coronary syndrome, 400 patients with acute coronary syndrome who underwent PCI were treated with Xuesaitong soft capsules (mainly containing ginsenosides) for 12 weeks.",[58],"Acute Coronary Syndrome",[60,61,62],"Acute coronary syndrome","traditional Chinese medicine","Total saponins of Panax notoginseng","2025-02-23",{"date":65,"type":35},"2025-02-25",{"date":67,"type":20},"2025-03-01",{"date":69,"type":20},"2026-12-01",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100572776","phase-1-study-on-the-effectiveness-and-mechanism-of-tong-xie-yao-fang-in-treating-diarrhea-predominant-irritable-bowel-syndrome-100572776","NCT06737666","Study on the Effectiveness and Mechanism of Tong-Xie-Yao-Fang in Treating Diarrhea-predominant Irritable Bowel Syndrome","Effects of Tong-Xie-Yao-Fang in Regulating Treg\u002FTh17 Imbalance of Diarrhea-predominant Irritable Bowel Syndrome by Trp-Kyn-AhR Pathway","Inclusion Criteria:\n\n* IBS-D patients and healthy volunteers meeting diagnostic criteria;\n* Aged between 18 and 70;\n* Have not taken antibiotics, steroids and other hormones, Chinese herbal preparations (including oral and intravenous injections), microecological preparations or probiotics such as yogurt in the past week.\n* Patients sign informed consent forms and are willing to receive appropriate treatment, and volunteers are willing to cooperate in taking blood, urine, stool and other samples.\n\nExclusion Criteria:\n\n* Patients with serious heart, liver, kidney and other major organ diseases, hematopoietic system, nervous system or mental diseases;\n* Other organic diseases of the digestive system (such as peptic ulcers), organic diseases such as tumors indicated by recent colonoscopy, or systemic diseases affecting digestive motility (such as hyperthyroidism, diabetes);\n* Need to continue to use drugs that may affect gastrointestinal function (antidiarrheals, antidepressants, anti-anxiety drugs, intestinal flora regulation drugs, antibiotics, etc.);\n* Have a history of drug allergy or severe food allergy for research purposes;\n* Patients under 18 years of age or over 75 years of age and pregnant or lactating women;\n* Severe negative life events occurred during treatment;\n* There is currently any form of psychotherapy in progress;\n* No intention to cooperate.",true,{"count":80,"type":20},60,[82],"PHASE1","Traditional Chinese Medicine focuses on the main pathogenesis of liver depression and spleen deficiency, and treats them from the perspective of soothing the liver and strengthening the spleen to treat on Diarrhea-predominant irritable bowel syndrome (IBS-D) . The classic formula for treating is the Tong-Xie-Yao-Fang (TXYF). Based on metabolomics and metagenomics, the research group studied the intestinal flora and host co metabolism of TXYF in the treatment of diarrhea predominant IBS-D, in order to clarify the mechanism of TXYF in the treatment of IBS-D.",[85],"Diarrhea-predominant Irritable Bowel Syndrome","RECRUITING","2024-12-15",{"date":89,"type":35},"2024-12-17",{"date":91,"type":35},"2023-05-29",{"date":93,"type":20},"2025-12",{"name":41,"class":42},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":5},"100523303","phase-4-efficacy-of-songling-xuemaikang-capsules-on-grade-1-hypertension-a-randomized-controlled-trial-100523303","NCT06093932","Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial","Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized, Multicenter, Double-blind, Placebo-controlled Trial","ESCIHP","Inclusion Criteria:\n\n* Age between 35-65 years old, male or female;\n* Grade 1 essential hypertension;\n* Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;\n* Sign the informed consent;\n\nExclusion Criteria:\n\n* Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg\u002Fdl, eGFR\\\u003C60ml\u002F(min·1. 73m2);\n* Gastrointestinal diseases, which may affect drug absorption;\n* Be allergic to the clinical trial medicine;\n* Pregnant or breastfeeding women, men who plan to give birth within half a year;\n* Combined with other serious primary diseases or malignant tumors;\n* Hyperlipidemia with or without taking lipid-lowering drugs;\n* Combined with left ventricular hypertrophy, ABI \\\u003C 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque;\n* Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes);\n* Other serious conditions in which is not fit for the study.","35 Years","65 Years",{"count":106,"type":20},100,[108],"PHASE4","The purpose of this study is:\n\n1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension.\n2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension.\n3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.",[111],"Hypertension,Essential",[113,114,115,116],"Songling Xuemaikang Capsules","Vascular remodeling","Grade 1 hypertension","Mild hypertension","2024-08-17",{"date":119,"type":35},"2024-08-20",{"date":121,"type":35},"2024-04-07",{"date":123,"type":20},"2027-12",{"name":41,"class":42},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":43},"100540057","phase-2-study-to-evaluate-the-efficacy-safety-and-tolerability-of-photodynamic-therapypdt-with-chlorin-e6-in-treating-moderate-to-severe-acne-100540057","NCT06311890","Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne","Inclusion Criteria:\n\n1. Subject is male or non-pregnant female 18 years of age and younger than 50 years of age.\n2. Subject has moderate to severe facial acne vulgaris.\n3. Subject has provided written informed consent.\n\nExclusion Criteria:\n\n1. People who are taking photosensitive drugs;\n2. Allergic to any component of the photosensitizer;\n3. porphyrins or allergies to porphyrins, with a history of photosensitivity;\n4. Pregnant or lactating women and those planning to become pregnant within 3 months;\n5. Oral or topical antibiotics, retinoids, glucocorticoids, peroxybenzoyl and other drugs within the past 1 month;\n6. Have a history of exposure to sunlight in the past 1 month, have received photoelectric treatment in the past 3 months, or have received facial grinding treatment in the past six months;\n7. are using vasodilators (such as nitroglycerin, etc.), beta blockers (such as metoprolol, etc.), anticoagulants (such as warfarin, etc.) and other drugs that easily cause facial capillary dilatation;\n8. Patients with facial rosacea, atopic dermatitis, hormone-dependent dermatitis and other facial skin-related diseases;\n9. Abnormal blood and urine routine, liver and kidney function, diseases of important organs and hematopoietic system that researchers believe are not suitable for clinical trials;\n10. Patients participating in other clinical trials at the same time.","50 Years",{"count":133,"type":20},46,[135],"PHASE2","This study aims to evaluate the clinical efficacy, safety and tolerability of a photodynamic therapy(PDT) based on a new photosensitizer, Chlorin-e6, in the treatment of moderate to severe acne. The hypothesis is that the therapy has good efficacy, safety and tolerability.",[138,139],"Acne","Photodynamic Therapy","2024-03-13",{"date":142,"type":35},"2024-03-15",{"date":144,"type":35},"2024-02-01",{"date":146,"type":20},"2026-09-30",{"name":41,"class":42},""]